ZVSA
Companies
NASDAQ
Zyversa Therapeutics Inc.
Health Care
$0.69
-$0.37 (-34.91%)
Price Chart
Overview
About ZVSA
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.
Market Cap
$3.7M
Volume
5.0M
Avg. Volume
4.8M
P/E Ratio
-0.11241666
Dividend Yield
0.00%
Employees
9.0
Company Information
Latest News for ZVSA
Risk & Correlation Analysis
Market Correlation
0.22
Low Correlation
Volatility
High (1.00)
Relative to market
Macro Factor Sensitivities
Interest Rates
High Sensitivity
Inflation
High Sensitivity
GDP Growth
Medium Sensitivity
Liquidity
High Sensitivity
Commodity Prices
High Sensitivity
Credit Quality
High Sensitivity
Portfolio Impact
Forecasts & Predictions
1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential
Technical Analysis
Based on technical indicators and chart patterns, ZVSA shows...
AI Sentiment Analysis
Market sentiment analysis indicates...
Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025